A5039725596- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- Salivary Gland Tumors Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Vasculitis and related conditions
- Calcium signaling and nucleotide metabolism
- Blood disorders and treatments
- Cancer-related gene regulation
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
- Genomics and Chromatin Dynamics
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Vrije Universiteit Amsterdam
2020-2025
Amsterdam University Medical Centers
2020-2025
Cancer Center Amsterdam
2023-2025
Amsterdam UMC Location Vrije Universiteit Amsterdam
2011-2024
Erasmus MC
2024
MRC Holland (Netherlands)
2024
Oncode Institute
2023-2024
Abstract Polymorphonuclear cells (neutrophils) are the first that arrive at sites of infections. According to current dogma, they involved in eliminating bacteria, after which die through apoptosis. We now demonstrate enhanced IgA-induced phagocytosis bacteria or beads by neutrophils led increased cell death. Nuclear changes and positivity for general death marker 7-aminoactinomycin D were observed, but absence annexin V membrane staining supported did not via apoptosis, contrast had...
Background The response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%–18% for patients with recurrent or metastatic head and neck squamous carcinoma (HNSCC). Detailed understanding of the tumor microenvironment (TIME) crucial in order explain improve this rate. HNSCCs arise at various anatomical locations including oral cavity, hypopharynx, larynx oropharynx. Studies directly comparing infiltration between sites are scarce. Since distinct could...
Abstract Neutrophils are the most abundant circulating FcR-expressing WBCs with potent cytotoxic ability. Currently, they recognized as promising effector cells for Ab-mediated immunotherapy of cancer, because their capacity to kill tumor is greatly enhanced by Ag-specific mAbs. The FcαRI represents FcR on neutrophils induction cell killing. However, mechanisms death that induced poorly understood. Because these can be used modulation anticancer treatment, we investigated neutrophil-mediated...
Background Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are options for recurrent/metastatic HNSCC; however, less than 20% patients respond. To increase this response rate, it is fundamental to our understanding the spatial tumor immune microenvironment (TIME). Methods In total, 53 HNSCC specimens were included. Using a seven-color multiplex immunohistochemistry panel we identified cells,...
Background/Objectives: Most studies on the interaction between immune system and cancer focus T-cells, whereas tumor-infiltrating B-lymphocytes (TIL-Bs) are still underrepresented. The aim of this study was to assess prognostic impact TIL-Bs in early- advanced-stage oral cavity squamous cell carcinoma (OCSCC). Methods: In total, 222 OCSCCs were studied. Consecutive sections stained for CD45 CD19. categorized as either “TIL-B-rich” or “TIL-B-poor”, survival both groups analyzed. Similar...
Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these changes are key characteristics cancer development. Nonetheless, some tumors show hardly any CNAs, a remarkable phenomenon in oncogenesis. Head neck squamous cell carcinomas (HNSCCs) arise either exposure to carcinogens, or infection with the human papillomavirus (HPV). HPV-negative HNSCCs generally characterized many CNAs frequent CDKN2A, TP53, FAT1, NOTCH1. Here, we present...
HPV-negative head and neck squamous cell carcinomas (HNSCCs) develop in precancerous changes the mucosal lining of upper-aerodigestive tract. These cells contain cancer-associated genomic cause primary tumors local relapses. Therapeutic strategies to eradicate these are very limited. Using functional screens, we identified therapeutic vulnerabilities premalignant cells, which shared with fully malignant HNSCC cells. We screened 319 previously tumor-lethal siRNAs on a panel cancer lines as...
Abstract Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type that arises in the epithelial cells lining mucosal surfaces of upper aerodigestive tract. Long-term survival patients with advanced disease stage remains disappointing current treatment options. We show tissue factor abundantly expressed on patient-derived HNSCC lines, xenograft material, biopsies from HNSCC. Tisotumab vedotin (TV) an antibody–drug conjugate (ADC) directed to factor, protein many tumors. tumors were...
<title>Abstract</title> Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these changes are key characteristics cancer development, but nonetheless some tumors show hardly any CNAs, a remarkable phenomenon in oncogenesis. Head neck squamous cell carcinomas (HNSCCs) arise either exposure to carcinogens, or infection with the human papillomavirus (HPV). HPV-negative HNSCCs generally characterized many CNAs frequent...
The immunosuppressive character of head and neck cancers may explain the relatively low response rates to antibody therapy targeting a tumor antigen, such as cetuximab, anti-PD-1 checkpoint inhibition. Immunostimulatory agents that overcome tumor-derived inhibitory signals could augment therapeutic efficacy, thereby enhancing elimination improving patient survival. Here, we demonstrate cetuximab treatment combined with immunostimulatory agonists for Toll-like receptor (TLR) 2 induces...
<p>Schematic scheme of in vivo experiments</p>
<p>Schematic scheme of in vivo experiments</p>
<p>Improved efficacy of chemotherapy when combined with tisotumab vedotin</p>
<div>Abstract<p>Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type that arises in the epithelial cells lining mucosal surfaces of upper aerodigestive tract. Long-term survival patients with advanced disease stage remains disappointing current treatment options. We show tissue factor abundantly expressed on patient-derived HNSCC lines, xenograft material, biopsies from HNSCC. Tisotumab vedotin (TV) an antibody–drug conjugate (ADC) directed to factor, protein many...
<p>Tumor growth curves FaDu xenografts</p>
<p>Improved efficacy of chemotherapy when combined with tisotumab vedotin</p>
<div>Abstract<p>Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type that arises in the epithelial cells lining mucosal surfaces of upper aerodigestive tract. Long-term survival patients with advanced disease stage remains disappointing current treatment options. We show tissue factor abundantly expressed on patient-derived HNSCC lines, xenograft material, biopsies from HNSCC. Tisotumab vedotin (TV) an antibody–drug conjugate (ADC) directed to factor, protein many...
<p>Tumor growth curves FaDu xenografts</p>